

**Study Category**

Antiretroviral Trial

**Title**

A Phase IIIB, Randomized, Open-Label, Multicentre Study of the Safety and Efficacy of GW433908 (700 mg BID) plus ritonavir (100 mg BID) Versus Lopinavir / ritonavir (400 mg/100 mg BID) when Administered in Combination with the Abacavir/Lamivudine (600 mg/ 300 mg) Fixed-Dose Combination Tablet QD in Antiretroviral-Naïve HIV-1 Infected Adults Over 48 Weeks

**Principal Investigator at TGH**

Dr. Sharon Walmsley

**Sponsor**

GlaxoSmithKline

**Brief Description of Study**

To compare the efficacy, safety and tolerability of Telzir boosted with Ritonavir compared to Kaletra when administered in combination with ABC/3TC FDC QD over 48 weeks in ART-naïve HIV-1 infected subjects. Patients are currently in the second year of follow-up with the plan to follow these patients for an additional 48 weeks.

**Contact Person**

Currently closed to enrollment

Anna Buss at (416) 340-4239, e-mail [anna.buss@uhn.on.ca](mailto:anna.buss@uhn.on.ca)